Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV
NCT05410496Phase 4Active, not recruiting
- Sponsor
- Taichung Veterans General Hospital
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Taichung Veterans General Hospital. Primary endpoints: Estimated Glomerular Filtration Rate at 144 weeks, Hepatitis B Virus Viral Load at 144 weeks and 1 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05410496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410496.